How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/chronic-lymphoid-leukemia-disease.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Chronic lymphoid leukemia, disease — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chronic lymphoid leukemia, disease (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Chronic lymphoid leukemia, disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Brukinsa	BGB-3111	Beigene Usa Inc	Kinase Inhibitor [EPC]	Tyrosine-protein kinase BTK	2019-01-01
Copiktra	DUVELISIB	Secura		Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	2018-01-01
Venclexta	venetoclax	AbbVie	BCL-2 Inhibitor [EPC]	Apoptosis regulator Bcl-2	2014-01-01
Gazyva	obinutuzumab	Roche	CD20-directed Cytolytic Antibody [EPC]	B-lymphocyte antigen CD20	2013-01-01
Imbruvica	ibrutinib	AbbVie	Kinase Inhibitor [EPC]	Tyrosine-protein kinase Blk	2013-01-01
Treanda	BENDAMUSTINE	Baxter	Alkylating Drug	Histone deacetylase 6	2008-01-01
Mabthera	Rituximab-Pvvr	Roche	Monoclonal antibody	CD20 antigen on pre-B and mature B-lymphocytes	1997-01-01
Mabthera	rituximab	Roche	CD20-directed Cytolytic Antibody [EPC]	B-lymphocyte antigen CD20	1997-01-01
Mabthera	rituxan	Roche	CD20-directed Cytolytic Antibody	B-lymphocyte antigen CD20	1997-01-01
Fludara	FLUDARABINE PHOSPHATE	Nihon Schering K.K.	Nucleoside Metabolic Inhibitor	Carbonic anhydrase 5A, mitochondrial	1991-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Roche · 4 drugs in Chronic lymphoid leukemia, disease
Baxter · 3 drugs in Chronic lymphoid leukemia, disease
AbbVie · 2 drugs in Chronic lymphoid leukemia, disease
Celyad Oncology SA · 1 drug in Chronic lymphoid leukemia, disease
Generic (originally Schering) · 1 drug in Chronic lymphoid leukemia, disease
Glaxo Grp Ltd · 1 drug in Chronic lymphoid leukemia, disease
GlaxoSmithKline · 1 drug in Chronic lymphoid leukemia, disease
Incyte Corporation · 1 drug in Chronic lymphoid leukemia, disease
Meir Medical Center · 1 drug in Chronic lymphoid leukemia, disease
Nihon Schering K.K. · 1 drug in Chronic lymphoid leukemia, disease
Rabin Medical Center · 1 drug in Chronic lymphoid leukemia, disease
Recordati · 1 drug in Chronic lymphoid leukemia, disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Chronic lymphoid leukemia, disease:

Cite this brief

Drug Landscape (2026). Chronic lymphoid leukemia, disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/chronic-lymphoid-leukemia-disease. Accessed 2026-06-10.

Chronic lymphoid leukemia, disease full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing